Cochrane
Library
Cochrane Database of Systematic Reviews
Melatonin treatment for newborns with hypoxic ischaemic
encephalopathy (Protocol)
Hurley T, O'Dea M, Aslam S, Aly H, Robertson N, Molloy E
Hurley T, O'Dea M, Aslam S, Aly H, Robertson N, Molloy E.
Melatonin treatment for newborns with hypoxic ischaemic encephalopathy (Protocol).
Cochrane Database of Systematic Reviews 2020, Issue 10. Art. No.: CD013754.
DOI: 10.1002/14651858.CD013754.
www.cochranelibrary.com
Melatonin treatment for newborns with hypoxic ischaemic encephalopathy (Protocol)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
Cochrane Database of Systematic Reviews
TABLE OF CONTENTS
HEADER.........................................................................................................................................................................................................
ABSTRACT.....................................................................................................................................................................................................
BACKGROUND..............................................................................................................................................................................................
OBJECTIVES..................................................................................................................................................................................................
METHODS.....................................................................................................................................................................................................
ACKNOWLEDGEMENTS................................................................................................................................................................................
REFERENCES................................................................................................................................................................................................
APPENDICES.................................................................................................................................................................................................
HISTORY........................................................................................................................................................................................................
CONTRIBUTIONS OF AUTHORS...................................................................................................................................................................
DECLARATIONS OF INTEREST.....................................................................................................................................................................
SOURCES OF SUPPORT...............................................................................................................................................................................
Melatonin treatment for newborns with hypoxic ischaemic encephalopathy (Protocol)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
1
1
2
3
3
6
7
10
13
13
13
14
i
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
Cochrane Database of Systematic Reviews
[Intervention Protocol]
Melatonin treatment for newborns with hypoxic ischaemic
encephalopathy
Tim Hurley1, Mary O'Dea2, Saima Aslam3, Hany Aly4, Nikki Robertson5, Eleanor Molloy2,6
1Department of Paediatrics, Trinity College Dublin, Dublin, Ireland. 2Paediatric and Child Health, Trinity College Dublin, Dublin, Ireland.
3Neonatology, National Maternity Hospital, Dublin, Ireland. 4Neonatology, Cleveland Clinic Children’s Hospital, Cleveland, OH, USA.
5Obstetrics and Gynaecology, University College London, London, UK. 6Department of Paediatrics, The National Children’s Hospital,
Tallaght, Dublin, Ireland
Contact address: Tim Hurley, hurleyti@tcd.ie.
Editorial group: Cochrane Neonatal Group.
Publication status and date: New, published in Issue 10, 2020.
Citation: Hurley T, O'Dea M, Aslam S, Aly H, Robertson N, Molloy E. Melatonin treatment for newborns with hypoxic
ischaemic encephalopathy (Protocol). Cochrane Database of Systematic Reviews 2020, Issue 10. Art. No.: CD013754. DOI:
10.1002/14651858.CD013754.
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
ABSTRACT
Objectives
This is a protocol for a Cochrane Review (intervention). The objectives are as follows:
To assess the effects and safety of melatonin compared to standard care, including therapeutic hypothermia, for improving survival and
reducing neurological sequelae in newborns with neonatal encephalopathy.
Melatonin treatment for newborns with hypoxic ischaemic encephalopathy (Protocol)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
1
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
BACKGROUND
Description of the condition
Neonatal encephalopathy (NE) is a clinically defined syndrome of
disturbed neurological function in the earliest days of life in term
and near-term newborns. Symptoms include an altered level of
consciousness, seizures, poor tone, and an inability to initiate or
maintain respiration (Volpe 2012). NE secondary to intrapartum
events is estimated to affect 1.16 million babies per year, with
the highest rates occurring in sub-Saharan Africa (Lee 2013). The
estimated incidence of NE is one to three per 1000 live births in
high-income settings, and up to 10 times higher in low- and middleincome settings (Kurinczuk 2010). NE is associated with multiorgan dysfunction (Shah 2004), disability, and a high incidence
of early mortality. The term NE does not specify aetiology or
pathogenesis (Molloy 2018), however there are many potential
causes including hypoxic-ischaemic encephalopathy (HIE) and
infectious, metabolic, coagulopathic, and placental causes. In up
to half of cases, no underlying cause is identified (Nelson 2012).
Regardless of the cause of NE, a final common pathway of hypoxiaischaemia leads to a cascade of events including oxidative stress
(Zhao 2016) and systemic inflammation (Hagberg 2015) that finally
result in cell death.
In the last decade, multiple clinical trials have demonstrated
the benefit of therapeutic hypothermia (TH) for newborns with
moderate to severe NE, in settings with access to neonatal intensive
care. There is clear evidence that TH reduces adverse outcomes
at 18 months of age (Jacobs 2013); this improvement persists into
childhood and there is widespread benefit to families, society, and
the economy (Azzopardi 2014). For these reasons, TH is standard
care for newborns with NE in high-income settings. In recent
years, the search for adjunct interventions to TH has focused
on other anti-inflammatory and anti-oxidant therapies, including
allopurinol, erythropoietin, and magnesium sulphate. Although
trials are ongoing, there is currently insufficient evidence to suggest
that any of these therapies have a significant effect on outcomes in
NE (Chaudhari 2012; Galinsky 2014; Robertson 2013; Wu 2015).
Despite treatment with TH, almost half of those with moderate
to severe NE die or survive with adverse neurodevelopmental
outcomes (Azzopardi 2009). In addition, recent data suggest that
newborns with mild NE (which is not routinely treated with TH)
are also at significant risk of neurodevelopmental disability (Chalak
2018). It is unclear whether TH is the best therapy for mild NE
(Kariholu 2018), and there is a critical need for new therapies —
either single or adjunct — in NE generally.
Description of the intervention
Melatonin (N-acetyl-5-methoxytryptamine) is a naturally occurring
hormone which is primarily released by the pineal gland in the brain
(Epstein 1997). The release of melatonin is regulated by sensors in
the eye which detect changes in light exposure. There is significant
24-hour variation in blood melatonin levels, with concentrations
being lower in the day and higher at night. Melatonin is an
important regulator of the circadian rhythm, but it also has antiinflammatory (Tarocco 2019), anti-oxidant (Reiter 2016), and antiapoptotic (Wang 2009) properties which make it a promising
intervention for neuroprotection in NE.
Cochrane Database of Systematic Reviews
Melatonin regulates the immune system in a number of ways. It acts
as an anti-inflammatory molecule under conditions of exacerbated
immune responses (Carrillo-Vico 2013). It exerts its influence on the
innate immune system by regulating the lifespan of leukocytes by
interfering with processes of cell death, regulating the release of
pro-inflammatory cytokines and leukotrienes, and modulating the
production of pro-inflammatory enzymes (Radogna 2010).
Melatonin is also a potent anti-oxidant. It indirectly stimulates
the production of anti-oxidant enzymes including superoxide
dismutase, glutathione peroxidase, and glutathione reductase,
and inhibits the production of the pro-oxidant enzyme nitric
oxide synthase (Reiter 2016). Melatonin is a direct free radical
scavenger, reducing the toxic effects of reactive oxygen species
and leading to further reduction in oxidative stress (Arteaga 2017).
Melatonin reacts with reactive oxygen species to form N1-acetylN2-formyl-5-methoxykynuramine (AFMK). AFMK has potent antioxidant effects and scavenges radical oxygen species as the final
melatonin compound involved in the free radical scavenging
cascade (Claustrat 2015).
Melatonin exerts it effect via several different pathways. It readily
crosses the blood-brain barrier and high levels accumulate in
the central nervous system (Tan 2010). Because neurons have a
high oxygen requirement, they are very vulnerable to oxidative
stress. Some effects occur indirectly via two G protein–coupled
receptors, M1 and M2, which are widely distributed throughout
the body and the brain (Stankov 1991), but melatonin also works
through its diverse anti-oxidative mechanisms which prevent
free-radical-induced oxidative damage to the electron transport
chain and mitochondrial DNA (Reiter 2016). Melatonin is also
believed to have a promising neuroprotective role through
reduction of neuroinflammation (Esposito 2010); and in models
of endotoxaemia it has been found to regulate the pro- and antiinflammatory cytokine network, modulate gene expression, and
preserve mitochondrial integrity (Li 2013).
Several exogenous forms of ligands that attach to melatonin
receptors are available and effective (Dubocovich 2010). However,
very high pharmacological doses of melatonin may be required
to exert anti-oxidant activity. In the piglet model, the beneficial
effects of melatonin have been found to be dose-dependent, with
earlier achievement of therapeutic levels (15 mg/L to 30 mg/L)
as important (Robertson 2019). Melatonin can be administered
by the enteral or intravenous route, although the recommended
route of administration for acute neuroprotection in the newborn
is intravenous as it results in greater bioavailability (Balduini
2019). Supplementation with melatonin has demonstrated a rapid
and sustained rise in plasma melatonin concentration in those
undergoing TH (Balduini 2019). Melatonin is primarily metabolised
in the liver via cytochrome CYP1A2 enzyme; this enzyme is
involved in the metabolism of a number of other commonly used
medications such as paracetamol and caffeine, which may affect
the bioavailability of melatonin (Papagiannidou 2014). Melatonin
has been studied in a number of conditions in the neonatal
population and has an excellent safety profile (Gitto 2009).
How the intervention might work
Brain injury in NE results from the consequences of HIE, which
include systemic inflammation, oxidative stress, and increased
apoptotic activity (Zhao 2016) and ultimately result in cell death.
Recent studies have shown that increased neutrophil activation
Melatonin treatment for newborns with hypoxic ischaemic encephalopathy (Protocol)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
2
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
(O’Hare 2015) and elevated circulating pro-inflammatory cytokines
(O'Hare 2017) are associated with worse outcomes in NE. Clinical
trials have demonstrated a reduction in circulating leukocytes and
pro-inflammatory chemokines in patients treated with TH (Jenkins
2013), suggesting that modulation of brain injury in NE occurs
via immunosuppression. Further studies have demonstrated
that administration of melatonin leads to a downregulation of
neutrophil activity and pro-inflammatory cytokines in the neonatal
population (El-Gendy 2017; Gitto 2004; Gitto 2005).
Newborns are more vulnerable to oxidative stress than older
individuals (Perrone 2013), and oxidative stress is a critical
contributor to brain injury in NE. Newborns with NE are unable
to compensate for the excess production of reactive oxygen
species following hypoxic or ischaemic insult. This in turn leads
to an accumulation of toxins and further systemic inflammation
which results in worsening brain injury. Studies of several
conditions involving oxidative stress in newborns, including
perinatal asphyxia, sepsis, and respiratory distress syndrome,
have demonstrated a reduction in oxidative stress with melatonin
supplementation (Gitto 2009).
In NE, oxidative stress combines with mitochondrial dysfunction to
result in mitochondrial energy failure, a key regulator of apoptotic
cell death (Lu 2015). Melatonin protects against neuron apoptosis
via a wide range of effects, including reduced release of cytochrome
c, increased expression of anti-apoptotic proteins, and reduced
expression of pro-apoptotic proteins. These actions help prevent
excess mitochondrial permeability and stabilise the mitochondrial
membrane potential (Alonso-Alconada 2013), leading to reduced
apoptotic cell death.
Several animal models of NE have demonstrated improved
outcomes with melatonin supplementation. Neonatal rats with
HIE brain injuries were at lower risk of learning deficits and
behavioural asymmetry when treated with melatonin (Carloni
2008). Newborn mice with white matter brain lesions demonstrated
improved secondary repair of these lesions when treated with
melatonin (Husson 2002). A piglet model of HIE demonstrated
improved neuroprotection as measured by magnetic resonance
spectroscopy when melatonin treatment was combined with
TH, compared to TH alone (Robertson 2013). Lamb and rat
models of NE have demonstrated that the neuroprotective effects
of melatonin treatment are mediated through reduced proinflammatory markers, reduced apoptosis-mediated cell death and
reduced cerebral oxidative stress (Aridas 2018; Villapol 2011).
Melatonin has an excellent safety profile: it is well tolerated
both in high doses by adults, with no adverse effects on
sedation (Andersen 2016), and by children on long-term treatment,
with no suppression of endogenous melatonin secretion (Palm
1997). It has been studied in many conditions in the neonatal
population, including respiratory distress syndrome (Gitto 2004)
and neonatal sepsis (Gitto 2001), with no adverse effects reported.
The largest safety study of melatonin in the neonatal population,
a retrospective study of 85 neonatal patients enrolled in multiple
clinical trials of different conditions, demonstrated improved
clinical outcomes and no adverse events (Aversa 2012). Studies
have not demonstrated any evidence of toxicity, even when
administered at very high doses (Aversa 2012). Enteral and
intravenous administration of melatonin are feasible and have
demonstrated increased plasma concentration of melatonin. It has
also been shown following melatonin administration, neonates
Cochrane Database of Systematic Reviews
have reduced clearance and prolonged half-life compared to adults.
Hypothermia does not appear to cause any significant changes
in pharmacokinetics in the neonatal population (Balduini 2019),
therefore melatonin could make a good adjunct to HT.
Why it is important to do this review
Melatonin is not currently in routine use for infants with NE. There
are compelling data from animal studies and early clinical trials to
suggest melatonin is safe and may be effective as a neuroprotective
agent in infants with NE, either as an adjunct or single therapy. Our
aim is to perform a systematic review of clinical studies on the use
of melatonin for babies with NE.
OBJECTIVES
To assess the effects and safety of melatonin compared to standard
care, including therapeutic hypothermia, for improving survival
and reducing neurological sequelae in newborns with neonatal
encephalopathy.
METHODS
Criteria for considering studies for this review
Types of studies
We will include all randomised and quasi-randomised controlled
trials comparing the use of melatonin with standard care for
patients with neonatal encephalopathy.
Types of participants
We will include infants born at or beyond 35 weeks' gestation, with
no major congenital malformations at birth and meeting any of the
following criteria.
1. Evidence of perinatal asphyxia, with each enrolled infant
satisfying at least one of the following criteria
a. Apgar score of five or less at 10 minutes
b. Mechanical ventilation or resuscitation at 10 minutes
c. Cord pH of less than 7.1, or an arterial pH of less than 7.1 or
base deficit of 12 or more within 60 minutes of birth
2. Evidence of encephalopathy according to Sarnat staging (Sarnat
1976)
a. Stage 1 (mild): hyperalertness, hyperreflexia, dilated pupils,
tachycardia, absence of seizures
b. Stage 2 (moderate): lethargy, hyperreflexia, miosis,
bradycardia, seizures, hypotonia with weak suck and Moro
c. Stage 3 (severe): stupor, flaccidity, small to mid-position
pupils that react poorly to light, decreased stretch reflexes,
hypothermia and absent Moro reflex
3. Severity of encephalopathy according to Thompson Score
(Thompson 1997)
a. Score 0 to 10 (mild)
b. Score 11 to 14 (moderate)
c. Score 15 or more (severe)
Types of interventions
The intervention will be melatonin supplementation, by oral or
intravenous administration, given to patients with NE within the
first week of life. The comparison will be with standard treatment
for NE, including TH.
Melatonin treatment for newborns with hypoxic ischaemic encephalopathy (Protocol)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
3
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
Types of outcome measures
Primary outcomes
1. Composite of death or long-term major neurodevelopmental
disability, defined as a diagnosis of cerebral palsy (CP); Gross Motor
Function Classification System (GMFCS) score of three or more;
developmental delay, defined as a score on any standardised infant
developmental assessment of more than two standard deviations
below the mean; intellectual disability, defined as intelligence
quotient (IQ) of more than two standard deviations below the
mean; visual impairment, defined as visual acuity of less than 6/60
in both eyes; sensorineural hearing loss, defined as unable to hear
sounds less than 40 decibels; or the need for more than one anticonvulsant medication for seizure control. Long-term outcomes
will be reported for all studies that have evaluated children after 18
months of age.
Secondary outcomes
1. Mortality
a. Early (within the first week of life)
b. Late (within the first year of life)
c. At 18 months or final follow-up assessment
2. Each component of major neurodevelopmental disability
assessed at more than 18 months of age
a. Cerebral palsy (Richards 2013)
b. Gross Motor Function Classification System of three or more
(McDowell 2008)
c. Developmental delay (Johnson 2014): defined as a score on
any standardised infant developmental assessment of more
than two standard deviations below the mean
d. Intellectual disability (Schalock 2007): defined as IQ of more
than two standard deviations below the mean
e. Visual impairment (Dandona 2006): defined as visual acuity
of less than 6/60 in both eyes
f. Sensorineural hearing impairment (Morzaria 2004): defined
as unable to hear sounds less than 40 decibels
3. Abnormal magnetic resonance imaging (Barkovich 1998)
4. Multiorgan dysfunction (Shah 2004)
5. Use of anti-convulsant medications
Search methods for identification of studies
We will use the criteria and standard methods of Cochrane and
Cochrane Neonatal (see the Cochrane Neonatal standard search
strategy).
Electronic searches
We will conduct a comprehensive search of databases including:
the Cochrane Central Register of Controlled Trials (CENTRAL 2020,
current issue) in the Cochrane Library; Ovid MEDLINE Epub Ahead
of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE
Daily and Ovid MEDLINE (1946 to current); and CINAHL (1981 to
current). We will not apply language restrictions to the searches. We
include the MEDLINE search in Appendix 1, which will be translated
into the other databases using the standard search strategy of
Cochrane Neonatal (Appendix 2).
We will search clinical trial registries for ongoing or
recently completed trials. We will search The World Health
Organization’s International Clinical Trials Registry Platform
Cochrane Database of Systematic Reviews
(ICTRP) (www.who.int/ictrp/search/en/) and the National Library
of Medicine’s ClinicalTrials.gov (clinicaltrials.gov) via CENTRAL.
Additionally, we will search the ISRCTN Registry for any unique
trials not found through the CENTRAL search.
Searching other resources
We will search the reference lists of previous reviews, and trials
included in the current review, for citations and cross-references.
We will search abstracts from conference proceedings, including
those of the joint European Neonatal Societies/European Society
for Paediatric Research (jENS/ESPR) (1960 to present), the Pediatric
Academic Societies (PAS) (1998 to present) and the Perinatal
Society of Australia and New Zealand (PSANZ) (1998 to present). We
will also consult experts in the subject area.
Data collection and analysis
We will collect and analyse data in accordance with the standard
methods of Cochrane Neonatal.
Selection of studies
Two review authors will independently assess the eligibility of all
retrieved studies for inclusion in the review. Disagreements will be
resolved by discussion between the two review authors. We will
assess studies in the usual consecutive format, starting with title
and abstract screening and subsequently full-text screening. We
will use Covidence software to facilitate this process (Covidence
2019). We will document the study selection process in a PRISMA
flow diagram.
Data extraction and management
Two review authors will independently perform data extraction
using a structured form. Differences will be resolved by discussion
between the two review authors. We will contact study authors to
request additional data from unpublished studies in abstract form,
if required. All analyses will be performed using Review Manager 5
software (Review Manager 2014).
Assessment of risk of bias in included studies
Two review authors (TH and MOD) will independently assess all
included trials using the Cochrane ‘Risk of bias’ tool. Each study will
be assigned a judgement of low, high, or unclear risk of bias for the
following domains (Higgins 2019).
1.
2.
3.
4.
5.
6.
7.
Sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding of participants and personnel (performance bias)
Blinding of outcome assessment (detection bias)
Incomplete outcome data (attrition bias)
Selective reporting (reporting bias)
Any other bias
Any disagreements will be resolved by discussion or by consulting a
third review author. See Appendix 3 for a more detailed description
of risk of bias for each domain.
Measures of treatment effect
We will express treatment effects for dichotomous outcomes using
summary risk ratio (RR), risk difference (RD), number needed
to treat for an additional beneficial outcome (NNTB) or number
Melatonin treatment for newborns with hypoxic ischaemic encephalopathy (Protocol)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
4
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
Cochrane Database of Systematic Reviews
needed to treat for an additional harmful outcome (NNTH), with
95% confidence intervals (CIs). For continuous outcomes, we will
express treatment effects using mean difference (MD) and 95%
CIs, where outcomes were measured using the same scale or in
the same way in the included studies. We will used standardised
mean difference (SMD) where studies assess the same outcome but
measure it in different ways.
Assessment of reporting biases
Unit of analysis issues
For cluster-randomised trials we will follow the guidance in the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2019) in order to avoid unit of analysis errors. We will conduct
the analysis at the same level as the allocation, using a summary
measurement from each cluster, so each cluster will become the
individual and will be analysed on this basis. Cross-over trials will
be excluded.
We will perform a meta-analysis of primary and secondary
outcomes, as well as pre-defined subgroups, subject to availability
of data. We will use standardised methodologies as described
in the Cochrane Handbook (Higgins 2019). Meta-analysis will be
conducted using the inverse variance method for continuous
outcomes, and the Mantel-Haenzel method for dichotomous
outcomes. We will use the random-effects model and present
all our results with 95% CIs. We will calculate the RR, RD, and
NNTB or NNTH if the RD is significant — each with 95% CIs — for
categorical outcomes. We will calculate the MD with 95% CIs for
continuous outcomes. Where continuous outcomes are measured
using different scales, the treatment effect will be expressed as SMD
with 95% CIs. For any outcomes where the included studies are not
sufficiently homogeneous, or where insufficient data are available
for meta-analysis, we will present a narrative synthesis.
Dealing with missing data
Certainty of evidence
Our strategy to deal with missing data will follow Cochrane
Handbook (Higgins 2019) guidance, as follows.
We will use the GRADE approach, as outlined in the GRADE
Handbook (Schünemann 2013), to assess the certainty of evidence
for the following (clinically relevant) outcomes: mortality, presence
of cerebral palsy, developmental delay or intellectual disability,
visual impairment or sensorineural hearing loss, abnormal
magnetic resonance imaging, multiorgan dysfunction, and use of
anti-convulsant medications.
Our primary outcome is a composite of dichotomous outcomes.
Each constituent of the primary outcome is clearly defined
by standardised criteria and expressed in standardised unit
measurement. Where outcomes are expressed as continuous data,
we will use internationally accepted cut-off values to categorise
participants, as outlined above.
1. Where possible, we will contact original investigators for missing
data.
2. Where possible, missing standard deviations will be imputed
using the coefficient of variation (CV), or calculated from other
available statistics including standard errors, CIs, t values, and P
values.
3. If the data are assumed to be missing at random, they will be
analysed without imputing any missing values.
4. If data cannot be assumed to be missing at random then the
missing outcomes will be imputed with replacement values,
assuming all to have a poor outcome.
5. If we are required to impute data, we will make explicit the
assumptions of any methods used.
6. We will perform sensitivity analyses to assess how sensitive
results are to reasonable changes in the assumptions that are
made.
7. We will address the potential impact of missing data on the
findings of the review in the 'Discussion' section.
Assessment of heterogeneity
We will estimate the treatment effects of individual trials and
examine heterogeneity among trials by inspecting the forest plots
and quantifying the impact of heterogeneity using the I2 statistic.
We will grade the degree of heterogeneity as: less than 25%
no heterogeneity; 25% to 49% low heterogeneity; 50% to 75%
moderate heterogeneity; more than 75% substantial heterogeneity.
If we note statistical heterogeneity (I2 > 50%), we will explore
the possible causes (e.g. differences in study quality, participants,
intervention regimens, or outcome assessments).
We will assess publication bias by creating funnel plots for metaanalyses consisting of at least 10 studies. If significant asymmetry
is found on visual inspection of the funnel plots, we will report this
in the corresponding results.
Data synthesis
Two review authors will independently assess the certainty of
the evidence for each of the outcomes above. We will consider
evidence from randomised controlled trials as high-certainty but
will downgrade the evidence by one level for serious (or two levels
for very serious) limitations based upon the following: design (risk
of bias), consistency across studies, directness of the evidence,
precision of estimates, and presence of publication bias. We will use
GRADEpro GDT (GRADEpro GDT) to create a ‘Summary of findings’
table to report the certainty of the evidence.
The GRADE approach results in an assessment of the certainty of a
body of evidence, of one of the following four grades.
1. High certainty: we are very confident that the true effect lies
close to that of the estimate of the effect.
2. Moderate certainty: we are moderately confident in the effect
estimate; the true effect is likely to be close to the estimate of the
effect, but there is a possibility that it is substantially different.
3. Low certainty: our confidence in the effect estimate is limited;
the true effect may be substantially different from the estimate
of the effect.
4. Very low certainty: we have very little confidence in the effect
estimate; the true effect is likely to be substantially different
from the estimate of effect.
Subgroup analysis and investigation of heterogeneity
Where there are sufficient studies, the following a priori subgroup
analyses will be conducted.
Melatonin treatment for newborns with hypoxic ischaemic encephalopathy (Protocol)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
5
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
1.
2.
3.
4.
Severity of NE
Timing of initiation of melatonin treatment
Method of melatonin administration
Dose of melatonin administration (0.5 mg/kg/day to 3.0 mg/kg/
day; 3.1 mg/kg/day to 7.5 mg/kg/day; 7.6 mg/kg/day to 20 mg/
kg/day)
5. Duration of melatonin administration (single dose; one to three
days; four to seven days; more than seven days)
6. Daily timing of melatonin administration (day (8am to 8pm);
night (8pm to 8am))
7. Adjunct use of TH
Sensitivity analysis
Where we identify substantial heterogeneity, we will conduct
sensitivity analysis to determine if the findings are affected by
Cochrane Database of Systematic Reviews
inclusion of only those trials considered to have used adequate
methodology with a low risk of bias (selection and performance
bias). We will report results of sensitivity analyses for primary
outcomes only.
ACKNOWLEDGEMENTS
The methods section of this protocol is based on a standard
template used by Cochrane Neonatal.
We would like to thank Cochrane Neonatal: Colleen Ovelman
(Managing Editor), Caitlin O'Connell Eckert (Assistant Managing
Editor), Roger Soll (Co-coordinating editor), and Bill McGuire (Cocoordinating Editor), who provided editorial and administrative
support. Carol Friesen, Cochrane Neonatal Information Specialist,
developed the Ovid MEDLINE search strategy, and Colleen Ovelman
peer-reviewed the strategy. Marie Berg and Jacqueline Ho peerreviewed the protocol.
Melatonin treatment for newborns with hypoxic ischaemic encephalopathy (Protocol)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
6
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
Cochrane Database of Systematic Reviews
REFERENCES
Additional references
Alonso-Alconada 2013
Alonso-Alconada D, Álvarez A, Arteaga O, Martínez-Ibargüen A,
Hilario E. Neuroprotective effect of melatonin: a novel therapy
against perinatal hypoxia-ischemia. International Journal
of Molecular Sciences 2013;14(5):9379-95. [DOI: 10.3390/
ijms14059379] [PMID: 23629670]
Andersen 2016
Andersen LP, Werner MU, Rosenkilde MM, Fenger AQ,
Petersen MC, Rosenberg J, et al. Pharmacokinetics of highdose intravenous melatonin in humans. Journal of Clinical
Pharmacology 2016;56(3):324-9. [DOI: 10.1002/jcph.592] [PMID:
26184078]
Aridas 2018
Aridas JDS, Yawno T, Sutherland AE, Nitsos I, Ditchfield M,
Wong FY, et al. Systemic and transdermal melatonin
administration prevents neuropathology in response to
perinatal asphyxia in newborn lambs. Journal of Pineal
Research 2018;64(4):e12479. [PMID: 29464766]
Arteaga 2017
Arteaga O, Álvarez A, Revuelta M, Santaolalla F, Urtasun A,
Hilario E. Role of antioxidants in neonatal hypoxic–ischemic
brain injury: new therapeutic approaches. International
Journal of Molecular Sciences 2017;18(2):265. [DOI: 10.3390/
ijms18020265] [PMID: 28134843]
Aversa 2012
Aversa S, Marseglia L, Arco A, D’Angelo G, Cusumano E, Barberi I,
et al. 1640 efficacy and safety of melatonin in neonates. Archives
Of Disease in Childhood 2012;97 Suppl 2:A464.
Azzopardi 2009
Azzopardi DV, Strohm B, Edwards AD, Dyet L, Halliday HL,
Juszczak E, et al. Moderate hypothermia to treat perinatal
asphyxial encephalopathy. New England Journal of Medicine
2009;361(14):1349-58. [DOI: 10.1056/NEJMoa0900854] [PMID:
19797281]
Azzopardi 2014
Azzopardi D, Strohm B, Marlow N, Brocklehurst P, Deierl A,
Eddama O, Goodwin J, Halliday HL, Juszczak E, Kapellou O,
Levene M. Effects of hypothermia for perinatal asphyxia
on childhood outcomes. New England Journal of Medicine
2014;371(2):140-9.
Balduini 2019
Balduini W, Weiss MD, Carloni S, Rocchi M, Sura L, Rossignol C,
et al. Melatonin pharmacokinetics and dose extrapolation after
enteral infusion in neonates subjected to hypothermia. Journal
of Pineal Research 2019;66(4):e12565. [DOI: 10.1111/jpi.12565]
[PMID: 30734962]
Barkovich 1998
Barkovich AJ, Hajnal BL, Vigneron D, Sola A, Partridge JC,
Allen F, et al. Prediction of neuromotor outcome in perinatal
asphyxia: evaluation of MR scoring systems. American Journal of
Neuroradiology 1998;19(1):143-9. [PMID: 9432172]
Carloni 2008
Carloni S, Perrone S, Buonocore G, Longini M, Proietti F,
Balduini W. Melatonin protects from the long-term
consequences of a neonatal hypoxic-ischemic brain injury
in rats. Journal of Pineal Research 2008;44(2):157-64. [DOI:
10.1111/j.1600-079X.2007.00503.x] [PMID: 18289167]
Carrillo-Vico 2013
Carrillo-Vico A, Lardone PJ, Álvarez-Sánchez N, RodríguezRodríguez A, Guerrero JM. Melatonin: buffering the
immune system. International Journal of Molecular Sciences
2013;14(4):8638-83. [DOI: 10.3390/ijms14048638] [PMID:
23609496]
Chalak 2018
Chalak LF, Nguyen KA, Prempunpong C, Heyne R, Thayyil S,
Shankaran S, et al. Prospective research in infants with
mild encephalopathy identified in the first six hours of life:
neurodevelopmental outcomes at 18–22 months. Pediatric
Research 2018;84(6):861. [DOI: 10.1038/s41390-018-0174-x]
[PMID: 30250303]
Chaudhari 2012
Chaudhari T, McGuire W. Allopurinol for preventing
mortality and morbidity in newborn infants with hypoxicischaemic encephalopathy. Cochrane Database of
Systematic Reviews 2012, Issue 7. Art. No: CD006817. [DOI:
10.1002/14651858.CD006817.pub3] [PMID: 22786499]
Claustrat 2015
Claustrat B, Leston J. Melatonin: physiological effects in
humans. Neurochirurgie 2015;61(2-3):77-84. [DOI: 10.1016/
j.neuchi.2015.03.002] [PMID: 25908646]
Covidence 2019 [Computer program]
Veritas Health Innovation Covidence. Melbourne, Australia:
Veritas Health Innovation, 2019.
Dandona 2006
Dandona L, Dandona R. Revision of visual impairment
definitions in the International Statistical Classification
of Diseases. BMC Medicine 2006;4(1):7. [DOI:
10.1186/1741-7015-4-7] [PMID: 16539739]
Dubocovich 2010
Dubocovich ML, Delagrange P, Krause DN, Sugden D,
Cardinali DP, Olcese J. International union of basic and clinical
pharmacology. LXXV. Nomenclature, classification, and
pharmacology of G protein-coupled melatonin receptors.
Pharmacological Reviews 2010;62(3):343-80. [DOI: 10.1124/
pr.110.002832] [PMID: 20605968]
El-Gendy 2017
El-Gendy FM, El-Hawy MA, Hassan MG. Beneficial effect of
melatonin in the treatment of neonatal sepsis. Journal of
Melatonin treatment for newborns with hypoxic ischaemic encephalopathy (Protocol)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
7
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
Maternal-Fetal & Neonatal Medicine 2017;31(17):1-16. [DOI:
10.1080/14767058.2017.1342794] [PMID: 28612668]
Epstein 1997
Brzezinski A. Melatonin in humans. New England
Journal of Medicine 1997;336(3):186-95. [DOI: 10.1056/
NEJM199701163360306] [PMID: 8988899]
Esposito 2010
Esposito E, Cuzzocrea S. Antiinflammatory activity of melatonin
in central nervous system. Current Neuropharmacology
2010;8(3):228-42. [DOI: 10.2174/157015910792246155] [PMID:
21358973]
Galinsky 2014
Galinsky R, Bennet L, Groenendaal F, Lear CA, Tan S, van Bel F, et
al. Magnesium is not consistently neuroprotective for perinatal
hypoxia-ischemia in term-equivalent models in preclinical
studies: a systematic review. Developmental Neuroscience
2014;36(2):73-82. [DOI: 10.1159/000362206] [PMID: 24854050]
Gitto 2001
Gitto E, Karbownik M, Reiter RJ, Tan DX, Cuzzocrea S,
Chiurazzi P, et al. Effects of melatonin treatment in septic
newborns. Pediatric Research 2001;50(6):756. [DOI:
10.1203/00006450-200112000-00021] [PMID: 11726736]
Gitto 2004
Gitto E, Reiter RJ, Cordaro SP, La Rosa M, Chiurazzi P,
Trimarchi G, et al. Oxidative and inflammatory parameters
in respiratory distress syndrome of preterm newborns:
beneficial effects of melatonin. American Journal of Perinatology
2004;21(4):209-16. [DOI: 10.1055/s-2004-828610] [PMID:
15168319]
Gitto 2005
Gitto E, Reiter RJ, Sabatino G, Buonocore G, Romeo C, Gitto P, et
al. Correlation among cytokines, bronchopulmonary dysplasia
and modality of ventilation in preterm newborns: improvement
with melatonin treatment. Journal of Pineal Research
2005;39(3):287-93. [DOI: 10.1111/j.1600-079X.2005.00251.x]
[PMID: 16150110]
Gitto 2009
Gitto E, Pellegrino S, Gitto P, Barberi I, Reiter RJ. Oxidative
stress of the newborn in the pre- and postnatal period and
the clinical utility of melatonin. Journal of Pineal Research
2009;46(2):128-39. [DOI: 10.1111/j.1600-079X.2008.00649.x]
[PMID: 19054296]
GRADEpro GDT [Computer program]
GRADEpro Guideline Development Tool [Software]. McMaster
University, 2020 (developed by Evidence Prime, Inc).
Hagberg 2015
Hagberg H, Mallard C, Ferriero DM, Vannucci SJ, Levison SW,
Vexler ZS, et al. The role of inflammation in perinatal brain
injury. Nature Reviews Neurology 2015;11(4):192-208. [DOI:
10.1038/nrneurol.2015.13] [PMID: 25686754]
Cochrane Database of Systematic Reviews
Higgins 2011
Higgins JP, Green S, editor(s). Cochrane Handbook for
Systematic Reviews of Interventions Version 5.1.0 (updated
March 2011). The Cochrane Collaboration, 2011. Available from
handbook.cochrane.org.
Higgins 2019
Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ,
Welch VA (editors). Cochrane Handbook for Systematic Reviews
of Interventions version 6.0 (updated July 2019). Cochrane,
2019. Available from www.training.cochrane.org/handbook.
Husson 2002
Husson I, Mesplès B, Bac P, Vamecq J, Evrard P, Gressens P.
Melatoninergic neuroprotection of the murine periventricular
white matter against neonatal excitotoxic challenge. Annals of
Neurology 2002;51(1):82-92. [PMID: 11782987]
Jacobs 2013
Jacobs SE, Berg M, Hunt R, Tarnow-Mordi WO, Inder TE,
Davis PG. Cooling for newborns with hypoxic ischaemic
encephalopathy. Cochrane Database of Systematic
Reviews 2013, Issue 1. Art. No: CD003311. [DOI:
10.1002/14651858.CD003311.pub3]
Jenkins 2013
Jenkins, DD, Lee T, Chiuzan C, Perkel JK, Rollins LG, Wagner CL,
et al. Altered circulating leukocytes and their chemokines in a
clinical trial of therapeutic hypothermia for neonatal hypoxic
ischemic encephalopathy. Pediatric Critical Care Medicine
2013;14(8):786-95. [DOI: 10.1097/PCC.0b013e3182975cc9]
[PMID: 23897243]
Johnson 2014
Johnson S, Moore T, Marlow N. Using the Bayley-III to assess
neurodevelopmental delay: which cut-off should be used?
Pediatric Research 2014;75(5):670. [DOI: 10.1038/pr.2014.10]
[PMID: 24492622]
Kariholu 2018
Kariholu U, Montaldo P, Markati T, Lally PJ, Pryce R,
Teiserskas J, et al. Therapeutic hypothermia for mild neonatal
encephalopathy: a systematic review and meta-analysis.
Archives of Disease in Childhood-Fetal and Neonatal Edition
2018;19. [DOI: 10.1136/archdischild-2018-315711] [PMID:
30567775]
Kurinczuk 2010
Kurinczuk JJ, White-Koning M, Badawi N. Epidemiology
of neonatal encephalopathy and hypoxic–ischaemic
encephalopathy. Early Human Development 2010;86(6):329-38.
[DOI: 10.1016/j.earlhumdev.2010.05.010] [PMID: 20554402]
Lee 2013
Lee AC, Kozuki N, Blencowe H, Vos T, Bahalim A, Darmstadt GL,
et al. Intrapartum-related neonatal encephalopathy incidence
and impairment at regional and global levels for 2010 with
trends from 1990. Pediatric Research 2013;74(S1):50. [DOI:
10.1038/pr.2013.206] [PMID: 24366463]
Melatonin treatment for newborns with hypoxic ischaemic encephalopathy (Protocol)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
8
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
Li 2013
Li CX, Liang DD, Xie GH, Cheng BL, Chen QX, Wu SJ, et al. Altered
melatonin secretion and circadian gene expression with
increased proinflammatory cytokine expression in early-stage
sepsis patients. Molecular Medicine Reports 2013;7(4):1117-22.
[DOI: 10.3892/mmr.2013.1331] [PMID: 23426900]
Lu 2015
Lu Y, Tucker D, Dong Y, Zhao N, Zhuo X, Zhang Q. Role of
mitochondria in neonatal hypoxic-ischemic brain injury. Journal
of Neuroscience and Rehabilitation 2015;2(1):1-14. [PMID:
27441209]
McDowell 2008
McDowell B. The gross motor function classification system
– expanded and revised. Developmental Medicine & Child
Neurology 2008;50(10):725.
Miller 2004
Miller SP, Latal B, Clark H, Barnwell A, Glidden D, Barkovich AJ,
et al. Clinical signs predict 30-month neurodevelopmental
outcome after neonatal encephalopathy. American Journal
of Obstetrics And Gynecology 2004;190(1):93-9. [DOI: 10.1016/
s0002-9378(03)00908-6] [PMID: 14749642]
Molloy 2018
Molloy EJ, Bearer C. Neonatal encephalopathy versus hypoxicischemic encephalopathy. Pediatric Research 2018;84(5):574.
[DOI: 10.1038/s41390-018-0169-7] [PMID: 30214023]
Morzaria 2004
Morzaria S, Westerberg BD, Kozak FK. Systematic review
of the etiology of bilateral sensorineural hearing loss in
children. International Journal of Pediatric Otorhinolaryngology
2004;68(9):1193-8. [DOI: 10.1016/j.ijporl.2004.04.013] [PMID:
15302152]
Nelson 2012
Nelson KB, Bingham P, Edwards EM, Horbar JD, Kenny MJ,
Inder T, et al. Antecedents of neonatal encephalopathy in the
Vermont Oxford Network encephalopathy registry. Pediatrics
2012;130(5):878-86. [DOI: 10.1542/peds.2012-0714] [PMID:
23071210]
O'Hare 2017
O'Hare FM, Watson RW, O'Neill A, Segurado R, Sweetman D,
Downey P, et al. Serial cytokine alterations and abnormal
neuroimaging in newborn infants with encephalopathy. Acta
Paediatrica 2017;106(4):561-7. [DOI: 10.1111/apa.13745] [PMID:
28097694]
O’Hare 2015
O’Hare FM, Watson RW, O’Neill A, Blanco A, Donoghue V,
Molloy EJ. Persistent systemic monocyte and neutrophil
activation in neonatal encephalopathy. Journal Of
Maternal-Fetal & Neonatal Medicine 2015;29(4):582-9. [DOI:
10.3109/14767058.2015.1012060] [PMID: 25694256]
Cochrane Database of Systematic Reviews
sleep-wake disturbances. Developmental Medicine
& Child Neurology 1997;39(5):319-25. [DOI: 10.1111/
j.1469-8749.1997.tb07438.x] [PMID: 9236698]
Papagiannidou 2014
Papagiannidou E, Skene DJ, Ioannides C. Potential drug
interactions with melatonin. Physiology & Behavior
2014;131:17-24. [DOI: 10.1016/j.physbeh.2014.04.016] [PMID:
24732412]
Perrone 2013
Perrone S, Tataranno LM, Stazzoni G, Ramenghi L, Buonocore G.
Brain susceptibility to oxidative stress in the perinatal period.
Journal of Maternal-Fetal & Neonatal Medicine 2013;28 Suppl
1:2291-5. [DOI: 10.3109/14767058.2013.796170] [PMID:
23968388]
Radogna 2010
Radogna F, Diederich M, Ghibelli L. Melatonin: a pleiotropic
molecule regulating inflammation. Biochemical Pharmacology
2010;80(12):1844-52. [DOI: 10.1016/j.bcp.2010.07.041] [PMID:
20696138]
Reiter 2016
Reiter RJ, Mayo JC, Tan DX, Sainz RM, Alatorre-Jimenez M, Qin L.
Melatonin as an antioxidant: under promises but over delivers.
Journal of Pineal Research 2016;61(3):253-78. [DOI: 10.1111/
jpi.12360] [PMID: 27500468]
Review Manager 2014 [Computer program]
Nordic Cochrane Centre, The Cochrane Collaboration Review
Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic
Cochrane Centre, The Cochrane Collaboration, 2014.
Richards 2013
Richards CL, Malouin F. Chapter 18: Cerebral palsy definition,
assessment and rehabilitation. In: Handbook of Clinical
Neurology. Elsevier, 2013:183-95.
Robertson 2013
Robertson NJ, Faulkner S, Fleiss B, Bainbridge A,
Andorka C, Price D, et al. Melatonin augments hypothermic
neuroprotection in a perinatal asphyxia model. Brain
2013;136(1):90-105. [DOI: 10.1093/brain/aws285] [PMID:
23183236]
Robertson 2019
Robertson NJ, Martinello K, Lingam I, Avdic-Belltheus A,
Meehan C, Alonso-Alconada D, et al. Melatonin as an adjunct
to therapeutic hypothermia in a piglet model of neonatal
encephalopathy: a translational study. Neurobiology Of Disease
2019;121:240-51.
Sarnat 1976
Sarnat HB, Sarnat MS. Neonatal encephalopathy following
fetal distress: a clinical and electroencephalographic study.
Archives of Neurology 1976;33(10):696-705. [DOI: 10.1001/
archneur.1976.00500100030012] [PMID: 987769]
Palm 1997
Palm L, Blennow G, Wetterberg L. Long-term melatonin
treatment in blind children and young adults with circadian
Melatonin treatment for newborns with hypoxic ischaemic encephalopathy (Protocol)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
9
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
Schalock 2007
Schalock RL, Luckasson RA, Shogren KA, BorthwickDuffy S, Bradley V, Buntinx WH, et al. The renaming
of mental retardation: understanding the change
to the term intellectual disability. Intellectual and
Developmental Disabilities 2007;45(2):116-24. [DOI:
10.1352/1934-9556(2007)45[116:TROMRU]2.0.CO;2] [PMID:
17428134]
Schünemann 2013
Schünemann H, Brożek J, Guyatt G, Oxman A, editor(s).
Handbook for grading the quality of evidence and the strength
of recommendations using the GRADE approach (updated
October 2013). GRADE Working Group, 2013. Available from
gdt.guidelinedevelopment.org/app/handbook/handbook.html.
Shah 2004
Shah P, Riphagen S, Beyene J, Perlman M. Multiorgan
dysfunction in infants with post-asphyxial hypoxic-ischaemic
encephalopathy. Archives of Disease in Childhood. Fetal
And Neonatal Edition 2004;89(2):F152-5. [DOI: 10.1136/
adc.2002.023093] [PMID: 14977901]
Stankov 1991
Stankov B, Fraschini F, Reiter RJ. Melatonin binding sites
in the central nervous system. Brain Research Reviews
1991;16(3):245-56. [PMID: 1665096]
Tan 2010
Tan DX. Melatonin and brain. Current Neuropharmacology
2010;8(3):161. [DOI: 10.2174/157015910792246263] [PMID:
21358966]
Tarocco 2019
Tarocco A, Caroccia N, Morciano G, Wieckowski MR, Ancora G,
Garani G, et al. Melatonin as a master regulator of cell death and
inflammation: molecular mechanisms and clinical implications
Cochrane Database of Systematic Reviews
for newborn care. Cell Death & Disease 2019;10(4):317. [DOI:
10.1038/s41419-019-1556-7] [PMID: 30962427]
Thompson 1997
Thompson CM, Puterman AS, Linley LL, Hann FM, Elst CW,
Molteno CD, et al. The value of a scoring system for hypoxic
ischaemic encephalopathy in predicting neurodevelopmental
outcome. Acta Paediatrica 1997;86(7):757-61. [PMID: 9240886]
Villapol 2011
Villapol S, Fau S, Renolleau S, Biran V, Charriaut-Marlangue C,
Baud O. Melatonin promotes myelination by decreasing white
matter inflammation after neonatal stroke. Pediatric Research
2011;69(1):51-5. [PMID: 20856166]
Volpe 2012
Volpe JJ. Neonatal encephalopathy: an inadequate term
for hypoxic–ischemic encephalopathy. Annals of Neurology
2012;72(2):156-66. [DOI: 10.1002/ana.23647] [PMID: 22926849]
Wang 2009
Wang X. The antiapoptotic activity of melatonin in
neurodegenerative diseases. CNS Neuroscience & Therapeutics
2009;15(4):345-57. [DOI: 10.1111/j.1755-5949.2009.00105.x]
[PMID: 19818070]
Wu 2015
Wu YW, Gonzalez FF. Erythropoietin: a novel therapy for
hypoxic–ischaemic encephalopathy? Developmental Medicine
& Child Neurology 2015;57(S3):34-9. [DOI: 10.1111/dmcn.12730]
[PMID: 25800490]
Zhao 2016
Zhao M, Zhu P, Fujino M, Zhuang J, Guo H, Sheikh I, et al.
Oxidative stress in hypoxic-ischemic encephalopathy: molecular
mechanisms and therapeutic strategies. International Journal
of Molecular Sciences 2016;17(12):2078. [DOI: 10.3390/
ijms17122078] [PMID: 27973415]
APPENDICES
Appendix 1. Ovid MEDLINE search strategy
Search strategy for Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Daily and Versions(R):
1. exp Melatonin/
2. melatonin.mp.
3. N-acetyl-5-methoxytryptamine.mp.
4. 1 or 2 or 3
5. exp Asphyxia/
6. exp Asphyxia Neonatorum/
7. exp Hypoxia-Ischemia, Brain/
8. exp Brain Ischemia/
9. exp Hypoxia/
10. exp Hypoxia, Brain/
11. exp Brain Injuries/
12. (brain injury or brain injuries).mp.
13. (neuroprotect* or neuro-protect* or neuro-restorative or neurorestorative).mp.
14. HIE.tw,kf.
15. encephalopath*.mp.
16. (hypoxi* adj2 ischaemi*).mp.
17. (hypoxi* adj2 ischemi*).mp.
Melatonin treatment for newborns with hypoxic ischaemic encephalopathy (Protocol)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
10
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
Cochrane Database of Systematic Reviews
18. asphyxia*.mp.
19. (anoxi* adj2 ischemi*).mp.
20. (anoxi* adj2 ischaemi*).mp.
21. or/5-20
22. exp infant, newborn/
23. (newborn* or new born or new borns or newly born or baby* or babies or premature or prematurity or preterm or pre term or low birth
weight or low birthweight or VLBW or LBW or infant or infants or 'infant s' or infant's or infantile or infancy or neonat*).ti,ab.
24. 22 or 23
25. randomized controlled trial.pt.
26. controlled clinical trial.pt.
27. randomized.ab.
28. placebo.ab.
29. drug therapy.fs.
30. randomly.ab.
31. trial.ab.
32. groups.ab.
33. or/25-32
34. exp animals/ not humans.sh.
35. 33 not 34
36. 24 and 35
37. randomi?ed.ti,ab.
38. randomly.ti,ab.
39. trial.ti,ab.
40. groups.ti,ab.
41. ((single or doubl* or tripl* or treb*) and (blind* or mask*)).ti,ab.
42. placebo*.ti,ab.
43. 37 or 38 or 39 or 40 or 41 or 42
44. 23 and 43
45. limit 44 to yr="2018 -Current"
46. 36 or 45
47. 4 and 21 and 46
Appendix 2. Cochrane Neonatal standard search strategy
The RCT filters have been created using Cochrane's highly sensitive search strategies for identifying randomised trials (Higgins 2019). The
neonatal filters were created and tested by the Cochrane Neonatal Information Specialist.
CENTRAL via CRS Web:
1. MESH DESCRIPTOR Infant, Newborn EXPLODE ALL AND CENTRAL:TARGET
2. infant or infants or infant’s or "infant s" or infantile or infancy or newborn* or "new born" or "new borns" or "newly born" or neonat* or
baby* or babies or premature or prematures or prematurity or preterm or preterms or "pre term" or premies or "low birth weight" or "low
birthweight" or VLBW or LBW or ELBW or NICU AND CENTRAL:TARGET
3. #1 or #2
MEDLINE via Ovid - Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Daily and Versions(R):
1. exp infant, newborn/
2. (newborn* or new born or new borns or newly born or baby* or babies or premature or prematurity or preterm or pre term or low birth
weight or low birthweight or VLBW or LBW or infant or infants or 'infant s' or infant's or infantile or infancy or neonat*).ti,ab.
3. 1 or 2
4. randomized controlled trial.pt.
5. controlled clinical trial.pt.
6. randomized.ab.
7. placebo.ab.
8. drug therapy.fs.
9. randomly.ab.
10. trial.ab.
11. groups.ab.
12. or/4-11
13. exp animals/ not humans.sh.
14. 12 not 13
15. 3 and 14
16. randomi?ed.ti,ab.
Melatonin treatment for newborns with hypoxic ischaemic encephalopathy (Protocol)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
11
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
Cochrane Database of Systematic Reviews
17. randomly.ti,ab.
18. trial.ti,ab.
19. groups.ti,ab.
20. ((single or doubl* or tripl* or treb*) and (blind* or mask*)).ti,ab.
21. placebo*.ti,ab.
22. 16 or 17 or 18 or 19 or 20 or 21
23. 2 and 22
24. limit 23 to yr="2018 -Current"
25. 15 or 24
CINAHL via EBSCOhost:
(infant or infants or infant’s or infantile or infancy or newborn* or "new born" or "new borns" or "newly born" or neonat* or baby* or babies
or premature or prematures or prematurity or preterm or preterms or "pre term" or premies or "low birth weight" or "low birthweight" or
VLBW or LBW) AND (randomized controlled trial OR controlled clinical trial OR randomized OR randomised OR placebo OR clinical trials
as topic OR randomly OR trial OR PT clinical trial)
Appendix 3. Risk of bias tool
We will use the standard methods of Cochrane and Cochrane Neonatal to assess the methodological certainty of the trials. For each trial,
we will seek information regarding the method of randomisation, blinding, and reporting of all outcomes of all the infants enrolled in the
trial. We will assess each criterion as being at low, high, or unclear risk of bias. Two review authors will separately assess each study. We
will resolve any disagreement by discussion. We will add this information to the 'Characteristics of included studies' table. We will evaluate
the following issues and enter the findings into the 'Risk of bias' table.
1. Sequence generation (checking for possible selection bias). Was the allocation sequence adequately generated?
For each included study, we will categorise the method used to generate the allocation sequence as:
• low risk (any truly random process, e.g. random number table; computer random number generator);
• high risk (any non-random process, e.g. odd or even date of birth; hospital or clinic record number); or
• unclear risk.
2. Allocation concealment (checking for possible selection bias). Was allocation adequately concealed?
For each included study, we will categorise the method used to conceal the allocation sequence as:
• low risk (e.g. telephone or central randomisation; consecutively numbered sealed opaque envelopes);
• high risk (open random allocation; unsealed or non-opaque envelopes, alternation; date of birth); or
• unclear risk
3. Blinding of participants and personnel (checking for possible performance bias). Was knowledge of the allocated intervention
adequately prevented during the study?
For each included study, we will categorise the methods used to blind study participants and personnel from knowledge of which
intervention a participant received. Blinding will be assessed separately for different outcomes or classes of outcomes. We will categorise
the methods as:
• low risk, high risk, or unclear risk for participants; and
• low risk, high risk, or unclear risk for personnel.
4. Blinding of outcome assessment (checking for possible detection bias). Was knowledge of the allocated intervention adequately
prevented at the time of outcome assessment?
For each included study, we will categorise the methods used to blind outcome assessment. Blinding will be assessed separately for
different outcomes or classes of outcomes. We will categorise the methods as:
• low risk for outcome assessors;
• high risk for outcome assessors; or
• unclear risk for outcome assessors.
5. Incomplete outcome data (checking for possible attrition bias through withdrawals, dropouts, protocol deviations). Were
incomplete outcome data adequately addressed?
Melatonin treatment for newborns with hypoxic ischaemic encephalopathy (Protocol)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
12
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
Cochrane Database of Systematic Reviews
For each included study and for each outcome, we will describe the completeness of data including attrition and exclusions from the
analysis. We will note whether attrition and exclusions were reported, the numbers included in the analysis at each stage (compared with
the total randomised participants), reasons for attrition or exclusion where reported, and whether missing data were balanced across
groups or were related to outcomes. Where sufficient information is reported or supplied by the trial authors, we will re-include missing
data in the analyses. We will categorise the methods as:
• low risk (less than 20% missing data);
• high risk (20% missing data or more); or
• unclear risk.
6. Selective reporting bias. Are reports of the study free of suggestion of selective outcome reporting?
For each included study, we will describe how we investigated the possibility of selective outcome reporting bias and what we found. For
studies in which study protocols were published in advance, we will compare prespecified outcomes versus outcomes eventually reported
in the published results. If the study protocol was not published in advance, we will contact study authors to gain access to the study
protocol. We will assess the methods as:
• low risk (where it is clear that all of the study's prespecified outcomes and all expected outcomes of interest to the review have been
reported);
• high risk (where not all the study's prespecified outcomes have been reported; one or more reported primary outcomes were not
prespecified outcomes of interest and are reported incompletely and so cannot be used; or the study fails to include results of a key
outcome that would have been expected to have been reported); or
• unclear risk.
7. Other sources of bias. Was the study apparently free of other problems that could put it at a high risk of bias?
For each included study, we will describe any important concerns we had about other possible sources of bias (for example, whether there
was a potential source of bias related to the specific study design or whether the trial was stopped early due to some data-dependent
process). We will assess whether each study was free of other problems that could put it at risk of bias as:
• low risk;
• high risk; or
• unclear risk.
If needed, we plan to explore the impact of the level of bias through undertaking sensitivity analyses.
HISTORY
Protocol first published: Issue 10, 2020
CONTRIBUTIONS OF AUTHORS
All authors contributed to writing and reviewing the protocol.
DECLARATIONS OF INTEREST
TH: under the supervision of Professor Eleanor Molloy, Tim Hurley is conducting research on the ex-vivo effects of melatonin treatment on
inflammation in newborns with NE. He is a PhD student funded by the Health Research Board of Ireland (Sources of support).
MO'D has no interests to declare.
SA has no interests to declare.
HA has conducted and published a randomised controlled pilot study of melatonin for neuroprotection in newborns with perinatal
asphyxia.
NR has conducted pre-clinical trials of melatonin for neuroprotection in animal model studies of neonatal encephalopathy. In 2016 her
institution licensed an orphan drug for melatonin for treatment of birth asphyxia to Chiesi Pharmaceuticals. Her institution (University
College London) received a research grant from Chiesi Pharmaceuticals for a pre-clinical study involving the use of their melatonin
formulation.
EM's institution receives a grant from the National Children's Research Centre Health Research Board Ireland. Professor Molloy is Associate
Editor in Chief for the journal Pediatric Research. Her institution receives support from Pediatric Research for Professor Molloy to travel to
ESPR and PAS. She is a National Children's Research Centre board member but receives no payment for this.
Melatonin treatment for newborns with hypoxic ischaemic encephalopathy (Protocol)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
13
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
Cochrane Database of Systematic Reviews
SOURCES OF SUPPORT
Internal sources
• Health Research Board, Ireland
Funding for PhD Student, Tim Hurley
External sources
• Vermont Oxford Network, USA
Cochrane Neonatal Reviews are produced with support from Vermont Oxford Network, a worldwide collaboration of health
professionals dedicated to providing evidence-based care of the highest quality for newborn infants and their families
Melatonin treatment for newborns with hypoxic ischaemic encephalopathy (Protocol)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
14